Physician profile
Paul D Smith
NPI 1891707915
$3,743.63
in general payments reported to CMS, 2019-2025
12 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $152 · 2021: $206 · 2022: $1,001 · 2023: $883 · 2024: $439 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $658.44 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander, Mentor Cpx 2 Breast Tissue Expander |
| Tela Bio, INC. | $500.09 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Integra Lifesciences Corporation | $480.90 | 2021-2025 | Integra, Surgimend, Omnigraft |
| Baxter Healthcare | $467.99 | 2019-2025 | Artiss, Tisseel, Floseal |
| Sientra, INC. | $445.28 | 2022 | |
| Kci USA, INC. | $300.31 | 2020-2023 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Abbvie INC. | $253.92 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Kerecis Limited | $218.83 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Innovation Technologies INC | $176.13 | 2022 | |
| Allergan, INC. | $125.95 | 2019 | |
| Smith+Nephew, INC. | $101.15 | 2022 | |
| Medtronic, INC. | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.